- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00336466
The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)
November 26, 2007 updated by: University of Calgary
The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS): A Randomized, Double-Blind, Placebo Controlled Proof-of-Concept Clinical Trial.
Context: Neurocognitive dysfunction complicates coronary artery bypass graft surgery. Neurocognitive dysfunction is a measurable problem with thinking. Erythropoietin may be a neuroprotectant.
Objective: To investigate the feasibility and safety of three doses of human recombinant erythropoietin to reduce neurocognitive dysfunction in coronary artery bypass graft patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Coronary artery bypass surgery (CABG) is performed each year on over 500,000 patients in the US and almost 30,000 patients in Canada to treat coronary artery disease.
However, it is complicated by a significant postoperative risk of neurologic sequelae, including stroke and neurocognitive dysfunction (NCD).
Clinically overt stroke, which may be seen in 1-4% of patients, is far less common than NCD, which is reported in approximately 50-75% of patients at discharge, 20-50% at 6 weeks and up to 40% at five years.Human recombinant erythropoietin (rh-Epo) is not only approved in this population for prophylactic use to reduce blood transfusions, but has become an agent of intense interest for neuroprotection as a result of in vitro data, animal experiments, and now, two promising preliminary trials in human patients.
There are not, however, any pilot data by which to estimate an appropriate dose or treatment effect of rh-Epo on NCD specifically.
It is imperative both to refine estimates of control group incidence rates, treatment effect and test variability in CABG, as well to demonstrate the feasibility and safety of a study protocol, prior to embarking on a larger randomized controlled trial powered with an adequate sample size to investigate the efficacy of rh-Epo in the reduction of peri-operative NCD.
We propose a six month prospective study in CABG patients to investigate the feasibility and safety of three prophylactic doses of human recombinant erythropoietin (rh-Epo) in a randomized, placebo controlled study.
The four study arms are: placebo, 375 U/kg, 750 U/kg, or 1500 U/kg of human recombinant erythropoietin intravenously divided in three doses, the day before, the day of and the day after surgery.
The primary outcomes of this pilot will be study feasibility and patient safety as measured by ICU and Hospital length of stay, 28 day all cause mortality, and incidence of morbidity including pure red cell aplasia (PRCA), stroke, myocardial infarction, re-operation, deep vein thrombosis, and pulmonary thromboembolism.
The secondary outcome will be the incidence of neurocognitive dysfunction among the four study arms and between placebo and rh-Epo at any dose.
As well, little is known about the pharmacology of rh-Epo in crossing the blood-brain barrier.
In those patients receiving a spinal anesthetic in addition to a general anesthetic as part of their normal care, CSF will be analyzed for rh-Epo concentration, and then compared to drug dose and serum level.
Study Type
Interventional
Enrollment
32
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- Foothills Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- First time cardiac surgical patients
- Elective or urgent on pump coronary artery bypass grafting (CABG)
- Age 45-75
- Signed, informed consent
Exclusion Criteria:
- Emergent CABG less than 48 hours from presentation
- Symptomatic cerebrovascular disease
- Atrial fibrillation
- Congestive Heart Failure within 2 weeks of surgery
- Malignancy or pre-malignant state within 5 years
- Significant Kidney disease (creatinine >150 umol/L)
- Significant Liver disease (Bilirubin > 20 umol/L)
- Significant Lung Disease (FEV1< 1.5 L, pO2 <70 on room air, pCO2 >45)
- Psychiatric Illness requiring medication
- Alcohol Abuse
- Less than Grade 7 education or inability to read
- Allergy to Eprex, past history of pure red cell aplasia
- Anemia or untreated iron deficiency
- Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety
|
Feasibility
|
Secondary Outcome Measures
Outcome Measure |
---|
Incidence of Neurocognitive Dysfunction
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: David Zygun, MD, University of Calgary and Calgary Health Region
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2004
Study Completion
May 1, 2005
Study Registration Dates
First Submitted
June 12, 2006
First Submitted That Met QC Criteria
June 12, 2006
First Posted (ESTIMATE)
June 13, 2006
Study Record Updates
Last Update Posted (ESTIMATE)
November 27, 2007
Last Update Submitted That Met QC Criteria
November 26, 2007
Last Verified
November 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17747
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Injury
-
Brent MaselThe Moody FoundationCompletedChronic Traumatic Brain InjuryUnited States
-
Toronto Rehabilitation InstituteCentre for Aging and Brain Health Innovation; Ontario Neurotrauma FoundationUnknownBrain Injuries, Traumatic | Brain Injury, Chronic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateCanada
-
BrainScope Company, Inc.RecruitingTBI (Traumatic Brain Injury) | Concussion, Brain | MTBI - Mild Traumatic Brain Injury | Closed Head InjuryUnited States
-
University of TurkuTurku University Hospital; The Finnish Funding Agency for Technology and Innovation... and other collaboratorsCompletedBrain Injuries | TBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Traumatic Brain Injury | Injury, Brain, TraumaticFinland
-
University of Sao Paulo General HospitalUnknownTraumatic Brain Injury | Severe Brain Injury | Closed Traumatic Brain InjuryBrazil
-
Center for Vision Development, New Market, MarylandUnknownBrain Injuries | Brain Injuries, Traumatic | Traumatic Brain Injury | Brain Injury, Chronic | Injury, Brain, TraumaticUnited States
-
Queen Mary University of LondonCompleted
-
Fondazione per la Ricerca Ospedale MaggioreCompletedBrain Injuries, Traumatic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateItaly
-
Assiut UniversityUnknown
-
Peking Union Medical College HospitalCompletedBrain-injury | Intracranial; Blood Vessel, InjuryChina
Clinical Trials on Human recombinant erythropoietin
-
Chugai PharmaceuticalCompletedChemotherapy Induced Anemia
-
Angde Biotech Pharmaceutical Co., Ltd.Recruiting
-
Tianjin SinoBiotech Ltd.Completed
-
University of CopenhagenCompleted
-
Fatih Sultan Mehmet Training and Research HospitalDr. Lutfi Kirdar Kartal Training and Research HospitalCompleted
-
Chugai PharmaceuticalCompletedChemotherapy Induced Anemia
-
Rigshospitalet, DenmarkUnknown
-
NICHD Neonatal Research NetworkNational Center for Research Resources (NCRR)CompletedAnemia, Neonatal | Infant, Small for Gestational Age | Infant, Premature | Infant, Low Birth Weight | Infant, NewbornUnited States
-
Cadila PharnmaceuticalsCompleted
-
Seoul National University Bundang HospitalCompletedAcute Myocardial InfarctionKorea, Republic of